Magnetic Nanoparticles and Quantum Dots for Diagnosis of Early Stage Ovarian Canc

描述(申请人提供)：Ocean NanoTech计划开发一种便携式、灵敏、高通量、低成本和用户友好的系统，用于卵巢癌的早期诊断，使用磁性纳米颗粒(MNPs)、量子点(Qds)和纳米电极阵列(NEA)，所有这些都集成在一次性的芯片实验室中。拟议的系统将由一个全自动化仪器组成，该仪器需要一次性的芯片实验室设备，该设备使用非常灵敏的高量子产率量子点和纳米电极阵列用于信号生成，用于诊断卵巢癌生物标记物的I阶段水平，浓度可能为d 1 ng/m L，在d 60分钟的检测中。它将是全自动的，允许高通量分析、高灵敏度和95%的可靠性，并将假阳性和假阴性降至最低。与现有的卵巢癌诊断方法不同，现有的诊断方法要么是侵袭性的，要么是在疾病进展过程中检测生物标志物太晚，导致生存率非常低，而拟议的系统有望检测到疾病的早期阶段，这是卵巢癌患者长期生存最有希望的方法。拟议的系统有望用于诊断早期卵巢癌，可用于以下非常重要的目的：1)对高危妇女进行定期监测；2)在出现模糊的临床症状时诊断疾病的早期阶段；3)监测用药期间卵巢癌生物标志物水平的变化；以及4)药物、疫苗或其他治疗分子的开发和疗效测试期间的检测系统。 公共卫生相关性：我们的目标是开发一种便携式、灵敏、高通量、低成本和用户友好的卵巢癌早期诊断系统，该系统使用一次性芯片实验室，集成了磁性纳米颗粒(MNPs)、量子点(Qds)和纳米电极阵列(NEA)的优点，用于荧光和纳米电化学检测。我们将开发MNPs、量子点和NEA的最佳组合，用于分离和检测多个卵巢癌生物标志物，以便对大约20,000名被诊断为卵巢癌的美国妇女进行早期诊断和可能的早期治疗，其中每年有15,000人死亡。

DESCRIPTION (provided by applicant): Ocean NanoTech proposes to develop a portable, sensitive, high throughput, low cost, and user friendly system for the early stage diagnosis of ovarian cancer using magnetic nanoparticles (MNPs), quantum dots (QDs), and a nanoelectrode array (NEA) all integrated in a disposable lab-on-a-chip. The proposed system will consists of a fully automated instrument that requires a disposable lab-on-a-chip device that uses very sensitive high quantum yield quantum dots and nanoelectrode array for signal generation in the diagnosis of stage I levels of ovarian cancer biomarkers at concentrations potentially d 1 ng/mL in a d 60 min assay. It will be fully automated allowing high throughput analysis, high sensitivity with > 95% reliability, and minimizing false positives and false negatives. Unlike existing diagnostic methods of ovarian cancer which are either invasive or detect biomarkers too late in the progress of the disease leading to very low survival rate, the proposed system is anticipated to detect early stages of the disease which is the most promising approach to the long term survival of ovarian cancer patients. The proposed system is anticipated to diagnose early stage ovarian cancer that can be used for the following very important purposes: 1) regular monitoring of high risk women; 2) diagnose early stage of the disease at the onset of vague clinical symptoms; 3) monitor changes in the ovarian cancer biomarker levels during medication; and 4) detection system during the development and efficacy testing of drugs, vaccine, or other therapeutic molecules. PUBLIC HEALTH RELEVANCE: Our goal is to develop a portable, sensitive, high throughput, low cost, and user friendly system for the early stage diagnosis of ovarian cancer that uses a disposable lab-on-a-chip that integrates the advantages of magnetic nanoparticles (MNPs), quantum dots (QDs), and nanoelectrode array (NEA) for fluorescence as well as nanoelectrochemical detection. We will develop the best combination of MNPs, QDs, and NEA for isolation and detection of multiple ovarian cancer biomarkers for early diagnosis and possible early treatment of approximately 20,000 American women who are diagnosed with ovarian cancer and of whom 15,000 die each year.